Engaging Parents of Children With Sickle Cell Disease in Shared Decision‐Making for Hydroxyurea: The ENGAGE‐HU Study

Findings suggest the toolkit may help parents feel more confident in deciding about hydroxyurea. Given the significant impacts of the COVID-19 pandemic on study implementation, the impact on hydroxyurea uptake requires additional exploration. Ultimately, the H-SDM toolkit may be most beneficial for clinics that do not routinely use a shared decision-making process for those considering hydroxyurea.

Authors

Institutions

Publication Details

Journal
Pediatric Blood & Cancer
Published
2025-03-06
DOI
https://doi.org/10.1002/pbc.31639
Citations
1
Primary Topic
Hemoglobinopathies and Related Disorders
Type
article
Field-Weighted Citation Impact
1.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Engaging Parents of Children With Sickle Cell Disease in Shared Decision‐Making for Hydroxyurea: The ENGAGE‐HU Study

Anna Hood, Francis J. Real, Cara Nwankwo, Lori E. Crosby et al.
1 citations
Pediatric Blood & Cancer
Hemoglobinopathies and Related Disorders
1.63
article

Engaging Parents of Children With Sickle Cell Disease in Shared Decision‐Making for Hydroxyurea: The ENGAGE‐HU Study

Anna Hood, Francis J. Real, Cara Nwankwo, Lori E. Crosby, Bridget Murphy, Allison A. King, Amy Sobota, Constance A. Mara, Alexis A. Thompson, Aimee K. Hildenbrand, Patricia E. Houston, Cecelia Calhoun, Michael R. DeBaun, Charles T. Quinn, Sherif M. Badawy, Kay L. Saving, Neha Bhasin, Lisa M. Shook, Steven Reader, Jean L. Raphael, Marsha Treadwell, Susan E. Creary, Kim Smith‐Whitley, Yolanda Johnson, Rogelle Hackworth, Cynthia Gipson
article en
1 citations

Abstract

Findings suggest the toolkit may help parents feel more confident in deciding about hydroxyurea. Given the significant impacts of the COVID-19 pandemic on study implementation, the impact on hydroxyurea uptake requires additional exploration. Ultimately, the H-SDM toolkit may be most beneficial for clinics that do not routinely use a shared decision-making process for those considering hydroxyurea.

Pediatric Blood & CancerVol. 72(5)
Northwestern University (US), Oklahoma State University (US), Cincinnati Children's Hospital Medical Center (US), Boston Medical Center (US), Lurie Children's Hospital (US), Nationwide Children's Hospital (US), St. Louis Children's Hospital (US), Children's Hospital of Philadelphia (US), Howard University (US), Thomas Jefferson University (US), Illinois College (US), University of California, San Francisco (US), Pfizer (United States) (US), Baylor College of Medicine (US), University of Manchester (GB), Yale University (US), University of Illinois Chicago (US), Nemours Children's Health System (US), Lurie Children's Hospital (US), UCSF Benioff Children's Hospital (US), Texas Children's Hospital (US), Children's Cancer Center (US), Indiana Hemophilia and Thrombosis Center (US), Vanderbilt University Medical Center (US), University of Cincinnati Medical Center (US)
Patient-Centered Outcomes Research Institute
Good health and well-being
Openalex Percentile: Top 20%
Hemoglobinopathies and Related Disorders
1.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.